News Sentiment

CPRX sentiment intelligence

Catalyst Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 31.47 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+0.1% over one week, +0.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Catalyst Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing

Market Reaction

Balanced read

55/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend active 0.4% over four weeks
Fair value 55.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 30
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 9
Stock Titan 5
ChartMill 4
simplywall.st 4
Sahm 3
Quartr 3
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 23
Deals and strategy 12
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 63
TradingView Direct company coverage

Price to sales forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX

This article provides the "Price to sales forward" financial metric for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX). It is presented within a financial data platform from TradingView, which also lists other company information and market data services. The content itself seems

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 11:11
Source
TradingView
MarketBeat Direct company coverage

Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026

As of June 15, 2026, Catalyst Pharmaceuticals (CPRX) had 7.95 million shares sold short, representing 7.25% of its public float, marking a 2.91% decrease from the previous report. The short interest ratio is 5.5 days to cover. This data indicates a slight decrease in bearish sent

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 21:39
Source
MarketBeat
Simply Wall Street Direct company coverage

Catalyst Pharmaceuticals (CPRX) Gets Early FTC Clearance For Angelini Merger

Catalyst Pharmaceuticals (NasdaqCM:CPRX) has received early U.S. Federal Trade Commission clearance for its proposed merger with Angelini Pharma, accelerating the regulatory review process. This clearance addresses a major regulatory hurdle for the acquisition, which is still con

Tone
Neutral 50/100
Event
Deals and strategy
Published
25 Jun 2026 08:10
Source
Simply Wall Street
Business Wire Direct company coverage

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. The law firm is scrutinizing whether the offered price of $31.50 per share adequately values the company and if the sales process was fair

Tone
Negative 40/100
Event
Market update
Published
24 Jun 2026 18:39
Source
Business Wire